Sergio Pinilla Zapater

Responsable De Administración at Certest Biotec, S.L.

Sergio Pinilla Zapater is a professional with extensive experience in administration and auditing. Currently serving as Responsable de Administración at CerTest Biotec, S.L. since February 2021, Sergio previously held roles at EY as Senior Auditor and Audit Assistant from September 2013 to January 2021, and as Ayudante Auditoría at Villalba, Envid y Cía Auditores SLP between November 2012 and July 2013. Sergio's educational background includes a Licenciatura en Administración y Dirección de Empresas, Contabilidad y Auditoría from Universidad de Zaragoza, a Máster en Auditoría from the same institution, and a Certificado NIA-ES in Auditoría from Universidad Pontificia Comillas.

Location

Zaragoza, Spain

Links

Previous companies


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Certest Biotec, S.L.

Highly specialized and customer-oriented, Certest Biotec consists of four divisions, including Raw Materials, Immunodiagnostics (Rapid Tests, Turbidimetry, and CLIA), Molecular Biology under the VIASURE brand, and Pharma. Certest Raw Materials provides high quality solutions for developing and manufacturing your IVD assays. Our expertise in protein expresión & purification, monoclonal antibodies develoment & manufacturing and primers & probes manufacturing offer to our customers a priceless support in their challenging proyects. Certest Immunodiagnostic -Rapid Test, Turbidimetry, CLIA- is committed to providing a comprehensive portfolio of diagnostic reagents for detecting infectious diseases and different markers, covering different needs of formats, types of use, throughput, precision and time from sample to result. VIASURE offers a reliable molecular diagnostic solution, from sample to intepretation of results, covering a wide range portfolio of products and enabling laboratories to better inform clinical decissions. The objective of Certest Pharma is to contribute with its technology to obtain better therapeutic products based on RNA. It is focused on three main áreas: RNAs, Delivery and Vaccines. Additionally, the expertise of our highly qualified personnel, currently numbering over 300 employees, is at the disposal of our customers, offering development and manufacturing services for the production of their own materials.